O-1057, a potent water-soluble cannabinoid receptor agonist with antinociceptive properties

British Journal of Pharmacology

Volumn 129, Issue 8, 2000, Pages 1577-1584

  Pertwee, Roger G ^a   Gibson, T Michael ^a   Stevenson, Lesley A ^a   Ross, Ruth A ^a   Banner, W Kenneth ^b   Saha, Bijali ^b   Razdan, Raj K ^b   Martin, Billy R ^c  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b ORGANIX INC   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Body temperature; Cannabinoids; Mouse tail flick test; Mouse vas deferens; O 1057; Spontaneous activity

Indexed keywords

4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; CANNABINOID; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR AGONIST; CANNABINOL DERIVATIVE; CYCLIC AMP; FORSKOLIN; O 1057; RIMONABANT; SODIUM CHLORIDE; TETRAHYDROCANNABINOL; UNCLASSIFIED DRUG; WATER;

ANIMAL CELL; ANIMAL TISSUE; ANTINOCICEPTION; ARTICLE; BINDING SITE; BRAIN MEMBRANE; CHO CELL; CONTROLLED STUDY; DRUG POTENCY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RECTUM TEMPERATURE; SOLUBILITY; VAS DEFERENS;

EID: 0034004184     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0703245     Document Type: Article

References (25)

1. BASILICO, L., PAROLARO, D., COLLEONI, M., COSTA, B. & GIAGNONI, G. (1999). Cross-tolerance and convergent dependence between morphine and cannabimimetic agent WIN 55,212-2 in the guinea-pig ileum myenteric plexus. Eur. J. Pharmacol., 376, 265-271.
2. BLISS, C.I. (1967). Statistics in Biology. McGraw Hill: New York.
3. 50) of an enzymatic reaction. Biochem. Pharmacol., 22, 3099-3108.
4. COLQUHOUN, D. (1971). Lectures on Biostatistics. Oxford University Press: Oxford, pp 279-343.
5. 9-tetrahydrocannabinol-induced responses and apparent agonist activity. J. Pharmacol. Exp. Ther., 277, 586-594.
6. COMPTON, D.R., RICE, K.C., DE COSTA, B.R., RAZDAN, R.K., MELVIN, L.S., JOHNSON, M.R. & MARTIN, B.R. (1993). Cannabinoid structure-activity relationships: correlation of receptor binding and in vivo activities. J. Pharmacol. Exp. Ther., 265, 218-226.
7. GREEN, A., O'SHAUGHNESSY, C., DISNEY, G. & MARSHALL, F. (1999). Reporter assays for human cannabinoid CB1 and CB2 receptors for the identification of novel agonists. Br. J. Pharmacol. (Proc. Suppl.), 126, 112P.
8. HYLDEN, J.L.K. & WILCOX, G.L. (1980). Intrathecal morphine in mice: a new technique. Eur. J. Pharmacol., 67, 313-316.
9. JOY, J.E., WATSON, S.J. & BENSON, J.A. (1999). Marijuana and Medicine. Assessing the Science Base. National Academy Press: Washington DC, pp 137-191.
10. MARTIN, B.R., THOMAS, B.F. & RAZDAN, R.K. (1995). Structural requirements for cannabinoid receptor probes. In: Cannabinoid Receptors, Pertwee, R.G (ed). Academic Press: London, pp. 35-85.
11. MATSUDA, L.A., LOLAIT, S.J., BROWNSTEIN, M.J., YOUNG, A.C. & BONNER, T.I. (1990). Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature, 346, 561-564.
12. MUNRO, S., THOMAS, K.L. & ABU-SHAAR, M. (1993). Molecular characterization of a peripheral receptor for cannabinoids. Nature, 365, 61-65.
13. 2 receptors. Pharmacol. Ther., 74, 129-180.
14. PERTWEE, R.G. (1999). Pharmacology of cannabinoid receptor ligands. Curr. Med. Chem., 6, 635-664.
15. PERTWEE, R.G. & GRIFFIN, G. (1995). A preliminary investigation of the mechanisms underlying cannabinoid tolerance in the mouse vas deferens. Eur. J. Pharmacol., 272, 67-72.
16. PERTWEE, R.G , STEVENSON, L.A., ELRICK, D.B., MECHOULAM, R. & CORBETT, A.D. (1992). Inhibitory effects of certain enantiomeric cannabinoids in the mouse vas deferens and the myenteric plexus preparation of guinea-pig small intestine. Br. J. Pharmacol., 105, 980-984.
17. PERTWEE, R.G., STEVENSON, L.A. & GRIFFIN, G. (1993). Cross-tolerance between delta-9-tetrahydrocannabinol and the cannabimimetic agents, CP 55,940, WIN 55,212-2 and anandamide. Br. J. Pharmacol., 110, 1483-1490.
18. RAZDAN, R K., ZITKO TERRIS, B., PARS, H.G., PLOTNIKOFF, N.P., DODGE, P.W., DREN, AT., KYNCL, J. & SOMANI, P. (1976). Drugs derived from cannabinoids. 2. Basic esters of nitrogen and carbocyclic analogs. J. Med. Chem., 19, 454-461.
19. RINALDI-CARMONA, M., BARTH, F., HÉAULME, M., SHIRE, D., CALANDRA, B., CONGY, C., MARTINEZ, S., MARUANI, J., NÉLIAT, G., CAPUT, D., FERRARA, P., SOUBRIÉ, P., BRELIÉRE, J.C. & LE FUR, G. (1994). SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Letts., 350, 240-244.
20. 8-tetrahydrocannabinol at cannabinoid receptors. Br. J. Pharmacol., 128, 735-743.
21. 8-tetrahydrocannabinol. J. Med. Chem., 41, 4400-4407.
22. 2 and receptor differentiation: a statistical analysis of competitive antagonism. Life Sci., 25, 637-654.
23. WELCH, S.P., HUFFMAN, J.W. & LOWE, J. (1998). Differential blockade of the antinociceptive effects of centrally administered cannabinoids by SR141716A. J. Pharmacol. Exp. Ther., 286, 1301-1308.
24. WILEY, J.L., COMPTON, D.R., DAI, D., LAINTON, J.A.H., PHILLIPS, M., HUFFMAN, J.W. & MARTIN, B.R. (1998). Structure-activity relationships of indole- and pyrrole-derived cannabinoids. J. Pharmacol. Exp. Ther., 285, 995-1004.
25. 1-tetrahydrocannabinol. Science, 177, 442-444.